FMS News and Press, Fresenius Medical Care AG From 01/12/20

The year closed with a bang with markets racing to new all-time highs almost every other day as the year came to an end. While the end-of-quarter months always rank among the highest in terms of dividend income December came in as only the 5th best month, disappointing at first, but fully expl...

Choosing between a stock that has a lot of upside and one that offers stability can be a difficult decision for investors, and it could make a significant impact on overall returns. Cara Therapeutics (NASDAQ: CARA) and Fresenius Medical Care AG & Co. (NYSE: FMS) are two companies tha...

Fresenius' rare underperformance of DaVita Four months ago, I covered on this site Fresenius Medical Care's ( FMS ) H1/19 results and came to the conclusion that the company was about fairly valued, despite the recent steep fall of its shares. In fact, the stock has roughly performed in-...

Value-oriented investors have been having a tougher time finding deals out there amid such a strong bull run in the markets over the course of 2019. But there are still good deals to be found in this market if you know where to look or have someone looking for you. For example, here are two st...

Stock continued to move upward in November setting new all-time highs across the board fueled by optimism regarding the phase 1 trade deal and a surprisingly calm month in terms of Trump's tweets. So far it has been another banner year for stocks but after last year's heavy December sell-of...

The following slide deck was published by Fresenius Medical Care AG & Co. KGaA in conjunction with this Read more ...

The following slide deck was published by Fresenius Medical Care AG & Co. KGaA in conjunction with this Read more ...

Introduction Better late than never. It`s update time, folks! I have used the last days with really bad weather here in Germany to research the last numbers and can now present you an update. Some users have already asked me about it – you can stop worry about me continueing my ar...

On Nov. 8,  FibroGen (NASDAQ: FGEN) and its partner AstraZeneca (NYSE: AZN) reported safety and efficacy data from a pooled analysis of six large phase 3 clinical trials with roxadustat, a drug aimed at treating anemia in patients with chronic kidney disease (CKD). In the non-dialys...

It's earnings season and across the board the results have mostly been better than expected, sending markets to all-time highs especially driven by the large gains in Microsoft ( MSFT ), Apple ( AAPL ) and UnitedHealth Group ( UNH ). Source: financeandmarkets.com It has gotten pretty qui...